Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention EVERTEC, the most common co-covered peer. They are corroborated in line with the beat average, carrying 4 original sources each against 4 for the same window.
Last mentioned: Feb 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention EVERTEC, the most common co-covered peer. They are corroborated in line with the beat average, carrying 4 original sources each against 4 for the same window. At 5, the average consequence score sits below the same-window beat average of 5.7. We currently track 1 Healthcare story that mention Natera, all published on February 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 31 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Natera. Shared-story counts are live from our verified record — not editorial picks.
Investors are closely monitoring upcoming earnings from Natera and Lantheus as bellwethers for the precision medicine and radiopharmaceutical sectors. These reports will highlight the scaling of molecular residual disease testing and the competitive dynamics of advanced prostate cancer imaging.
Source: markets.financialcontent.com · markets.financialcontent.com
Natera is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
